上海宣泰医药科技股份有限公司2025年半年度报告摘要

Core Viewpoint - The company plans to distribute a cash dividend of 0.25 yuan per 10 shares for the first half of 2025, amounting to a total of approximately 11.23 million yuan, which represents 24.62% of the net profit attributable to shareholders for the same period [5][9][10]. Financial Data - The net profit attributable to shareholders for the first half of 2025 is approximately 45.59 million yuan [9]. - The total distributable profit as of June 30, 2025, is approximately 233.73 million yuan [9]. Dividend Distribution Plan - The dividend distribution will be based on the total share capital after deducting shares held in the company's repurchase account, which totals 449,003,891 shares [5][9]. - The company will not conduct a capital reserve transfer to increase share capital or issue bonus shares in this distribution [5][9]. Board Decisions - The profit distribution plan was approved by the company's board of directors during meetings held on August 19 and August 21, 2025 [11][12]. Fund Management - The company raised approximately 424.84 million yuan through the issuance of shares, with a net amount of approximately 377.22 million yuan after deducting issuance costs [15][16]. - As of June 30, 2025, the remaining balance of the raised funds is approximately 63.25 million yuan, with 52.52 million yuan in a current account and 58 million yuan in structured deposits [18]. Use of Raised Funds - The company has utilized approximately 27.48 million yuan of the raised funds for investment projects in the first half of 2025 [16]. - There were no instances of using idle raised funds to temporarily supplement working capital during the reporting period [21].